Carb-X

Bacteriophage Therapy Summit
2020-08-27 - 2020-08-28 | Webinar
As the scientific community search for alternatives to broad spectrum antibiotics, phage therapy has re-emerged as a viable solution to tackle the global health challenge of anti-microbial resistance.
As such, the 2nd Bacteriophage Therapy Summit returns digitally as a dedicated platform for leaders in industry and academia to accelerate the discovery and translation of bacteriophage research into targeted therapeutics that demonstrate clinically significant results.
With a heavy translationally focused agenda including how to overcome bacterial resistance scaling-up manufacturing and showing clinical efficacy this is your opportunity to join your peers to strengthen your product development pipelines and forge collaborations to unlock the full potential of bacteriophage therapeutics.
View the full event guide for further details on speakers, content and how to join those who paving the way for bacteriophage-based therapeutics!

BIOCOM 4th AMR Conference: SME campus (Part II) | Focus on diagnostics
2020-08-27 06:00 - 07:00 (America/New_York) | Webinar
Moderator:

Betsy Wonderly Trainor, Alliance Director, CARB-X

Speakers:

Peter Haug – CFO & Co-Founder, Head of Business Development & Licensing, Noscendo GmbH
Piotr Gastrecki – CTO, ScopeFluidics
Rosemarie Preyer – GenID GmbH

PACCARB: Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
2020-09-09 - 2020-09-10 | Webinar
The September PACCARB meeting, held virtually, will focus on welcoming eight new liaison members and on the impact of COVID-19 and its affect on antimicrobial resistance (AMR). Topics will include presentations on the COVID-19 mortality rate due to secondary acquired infections, antibiotic stewardship practices during a pandemic, disruptions in the agricultural industry due to COVID-19 and the intersection of AMR and emergency preparedness.
This virtual public meeting is hosted by HHS and is open to the public. It will be held via webcast.The meeting can be accessed through a live webcast on the day of the meeting.
Live Webcast: www.hhs.gov/live
Click here to learn more.

Building, Funding, and Growing Successful Biotech Startups
2020-09-17 14:00 - 15:30 (America/New_York) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers include Cameron Bess, Project Officer, Antibacterials Branch, Division of CBRN Medical Countermeasures, BARDA.
Turning a good scientific idea into a successful biotech startup is a challenging journey.This panel will highlight several successful paths that scientists can take toward creating a successful biotech company. Learn what New York-area resources are available to turn your idea into a business and help you develop entrepreneurial skills.
The event will introduce funding and strategic programs available from IndieBio, the Center for Biotechnology, the National Institutes of Health (NIH), and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Speakers include:

Anton Xavier, Assistant Director of Technology and Business Development at the Center for Biotechnology.
Phuong Nguyen, Commercialization Fellow at the Center for Biotechnology.
Stephen Chambers, Managing Director of IndieBio in New York.
Matthew McMahon, Director of NIH’s Small Business Education and Entrepreneurial Development (SEED) Program.
Cameron Bess, Project Officer, Antibacterials Branch, Division of CBRN Medical Countermeasures, BARDA.

To learn more and register, click here.

Antimicrobial Resistance Fighter Coalition Webinar: Responding to difficult-to-treat infections: Role and responsibilities of governments, researchers, clinicians, industry and patients
2020-09-19 09:00 - 10:00 (America/New_York) | Webinar
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
Governments, researchers, and industry partners around the world have mobilized to develop diagnostics, therapeutics, and vaccines for COVID-19. The development of new recommendations and practices continue to be deployed to slow the spread of COVID-19. The burden of drug-resistant infections could surpass COVID-19. Drugs like antibiotics are a vital tool for modern medicine, used to prevent and treat infections. As drug-resistant infections are becoming more common, modern medicine as we know it is at risk and much like COVID-19, it has the potential to overwhelm our healthcare structure. What changes are needed to reshape strategies for combatting antimicrobial resistance globally?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

Chatham House Webinar: Creating a New Generation of Antibiotics
2020-09-22 07:00 - 08:00 (America/New_York) | Webinar
Participants include Kevin Outterson, Executive Director of CARB-X.
The world needs a new generation of antibiotics to address the rapid growth in antibiotic-resistant bacteria. The UK government’s 2014 Review on Antimicrobial Resistance estimated that such bacteria could result in the deaths of 10 million people a year by 2050 and an accumulated cost of up to $100 trillion to the global economy. Despite this urgent need, there remain few new antibiotics in development due to a lack of commercial viability for pharmaceutical companies with a 2019 Chatham House report highlighting the lack of progress being made on critical recommendations to tackle antimicrobial resistance.
This event will discuss the urgency of the development of new antibiotics and recent efforts to address the funding gap. What is the significance of the rise of antibiotic-resistant bacteria? What are the challenges at the intersection of increasing demand for new antibiotics and their commercial viability? Does the recent announcement of a new fund from the pharmaceutical industry represent a major shift, or just the beginning, of what is needed?
Participants:

Thomas Cueni, Director General, IFPMA
Jim O’Neill, Chair, Chatham House
Kevin Outterson, Associate Fellow, Global Health Programme, Chatham House
Laura Piddock, Professor of Microbiology; Deputy Director of the
Institute of Microbiology and Infection, University of Birmingham
Chair: Emma Ross, Senior Research Fellow, Global Health Programme, Chatham House

To learn more, click here.

ESCMID Conference on Coronavirus Disease (ECCVID)
2020-09-23 - 2020-09-25 | Webinar
Speakers include Kevin Outterson, Executive Director of CARB-X.
The ESCMID Conference on Coronavirus Disease (ECCVID) will take place online from Wednesday 23rd to Friday 25th September 2020 and will cover all aspects of COVID-19. ECCVID will feature a comprehensive scientific programme that will span a wide range of topics surrounding this emerging threat.
COVID-19 is a major public health incident which has brought about significant challenges and uncertainties with respect to diagnostics, therapeutics and infection prevention and control. We are learning continually about the new SARS-CoV-2 virus and an international scientific event that brings together the latest research and scientific evidence is very timely. ECCVID will offer excellent opportunities to showcase the latest findings, share experiences and knowledge and demonstrate practical techniques and guidance.
Internationally renowned clinical microbiologists, infectious diseases specialists and experts from related disciplines will present their work and latest findings on COVID-19, during the event.
Click here to learn more.
Click here to view the programme.
Click here to register.

Antimicrobial Resistance Fighter Coalition Webinar: The global movement of microorganisms: Tracking the spread of difficult-to-treat infections
2020-09-24 09:00 - 10:00 (America/New_York) | Webinar
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
Tracking the spread of COVID-19 has been critical to the global public health response. This information allows hospitals to prepare for surges, governments to deploy testing strategies, and citizens to modify their behavior appropriately. But while information about COVID-19 is readily and publicly available, the world still struggles to monitor and track the spread of drug resistant infections.How should global monitoring and data sharing evolve to combat antimicrobial resistance?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

Live Webinar: GARDP/REVIVE – Moving from preclinical to clinical-stage: Challenges and opportunities
2020-09-24 09:30 - 11:30 (America/New_York) | Webinar
Speakers:

Value of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience – Bala Subramanian, Bugworks Research Inc.
Amicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections – Michael P. Bevilacqua, Amicrobe, Inc.
Discovery and development of microbiome therapeutics using reverse translation – Matthew Henn & Chris Ford, Seres
Therapeutics Development of a multi-component toxoid vaccine for S. aureus – Regulatory challenges and opportunities – M. Javad Aman & Catherine Bernard, Integrated BioTherapeutics
Regulatory challenges for RaPID/BSI – culture-free identification and characterization of bloodstream infections – David Steinmiller, HelixBind Inc.

Moderator: Erin Duffy, CARB-X
The presentation will be followed by a Q&A session.
Register now for this live webinar.

World Vaccine Congress
2020-09-28 - 2020-10-01 | Webinar
CARB-X speakers include Nadia Cohen, Alliance Manager.
The World Vaccine Congress is an award-winning series of conferences and an exhibition that has grown to become the largest and most established vaccine meeting of its kind across the globe. Due to the global pandemic, we have made a decision to run the 2020 congress VIRTUALLY. To mobilize, coordinate and align funding to enable the research needed to tackle this crisis and stop the outbreak, and commit with our experts how you can learn mechanisms for continuing scientific interactions and collaborations, now and beyond the congress.

Click here to view the agenda.
Click here to learn more.
Click here to register.
Nadia Cohen will be participating in the panel, World Vaccine Congress: Success case study 2 – Partnering with a non-profit for the first toxoid based multivalent vaccine for MRSA, on September 29 at 2:40 pm – 3:10 pm ET.

Longitude Prize Sprint Workshop: How to Attract Investment
2020-09-30 09:00 - 12:15 (America/New_York) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Recent CARB-X graduate, Specific Diagnostics, will be participating in this workshop.
This workshop will be a forum for start-up and SMEs developing diagnostic tests to:

Hear from successful entrepreneurs who have built diagnostic companies, what do they think were their key factors for success?
Hear from venture capital investors about what they expect and need before making investments.
Meet in small break-out sessions in which you will interact directly with other medtech startups who have built or are in midst of building their enterprises and share insights.
Participate in panel discussion where you can ask both medtech leaders and venture capital fund managers about the intricacies and nuances of dilutive fund raise.

Note: this webinar is the second in the Longitude Prize Sprint series.
More details can be found on the Longitude Prize website here. Registration is limited, if you have trouble registering please send an email to longitude.prize@nesta.org.uk
To view the agenda, click here.
To register, click here.

Boston Area Antimicrobial Resistance Network (BAARN) Meeting
2020-10-02 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
CARB-X speakers include Su Chiang, Alliance Manager.
The 7th BAARN meeting will bring together the leading voices in academia and industry to addresss a defining global health crisis of our age: antibiotic resistant infection.
This year will be BAARN’s inaugural virtual meeting. We are using online platforms to present an amazing lineup of researchers and innovators, accessible to anyone with an internet connection. The event will stream on YOUTUBE LIVE. Zoom and YouTube Live links will be sent upon registration.
This event is co-coordinated by the Harvard Microbial Sciences Initiative and the Harvard Infectious Disease Institute.
To learn more, click here.
To register, click here.

World Antimicrobial Resistance Congress 2020
2020-10-08 - 2020-10-09
Erin Duffy, CARB-X Chief of R&D, is the chairperson of the event as well as a participant in a number of panels. Other participants from CARB-X include Kevin Outterson (Executive Director), Richard Alm (Therapeutic R&D Alliance Director), Ed Buurman (Prevention R&D Alliance Director) and Betsy Wonderly Trainor (Diagnostic R&D Alliance Director).

The 6th annual World Antimicrobial Resistance Congress will be held virtually October 8-9, 2020. It will showcase more than 250 presentations, including speakers from CARB-X funded companies, Forge and Entasis.
Anti-microbial resistance continues to grow as a critical healthcare crisis globally. The number of deaths attributed to this epidemic is exponentially increasing, and most measures and policies to combat AMR are deemed insufficient.Since 2015, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space to meet, brainstorm ideas and formulate initiatives that can effectively tackle this pressing issue.
Industry leaders, innovative technology and solution providers, public authorities, international organizations, infectious disease clinicians, pharmacists and microbiologists are some of the 1,000+ attendees from over 50 countries who will gather virtually this October 2020 at the World Anti-Microbial Resistance Congress.
If you work in these key areas of AMR, then you must attend the World Anti-Microbial Resistance Congress 2020!

Click here for more information.
Click here to register.

Antimicrobial Resistance Fighter Coalition Webinar: Prevention is stronger than a cure
2020-10-15 09:00 - 10:00 (America/New_York) | Webinar
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
Preventing drug resistant infections reduces the use of antibiotics and improves patient outcomes. Infection control practices, from simple hand-washing to global vaccination, and the use of effective infection prevention measures are key tools to combat COVID-19 and AMR. How has the COVID-19 pandemic informed our infection prevention efforts for healthcare systems and individuals around the world?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

5th Microbiome Movement - Drug Development Summit 2020
2020-10-19 - 2020-10-21 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
The study of the human microbiome remains one of the most exciting frontiers in modern medicine that if targeted correctly, has the potential to benefit millions of patients suffering from numerous diseases. However, the potential for effective medicines powered by the microbiome is matched by the unique challenges in developing them.
The Microbiome Movement – Drug Development Summit returns as the “must attend meeting for the translational microbiome community” to help cutting-edge pharmaceutical and academic researchers pursue the causal role of the human microbiome in disease to help deliver a new generation of targeted therapeutics, biomarker and diagnostics that demonstrate consistent clinical outcomes and predictabe MoAs.
So whether you’re part of a microbiome-focused biotech, a pharmaceutical organization assessing this exciting field, or an academic researcher with breakthrough findings, join the Microbiome Movement as we explore the global advances in translational microbiome research, and meet like-minded peers who are continuing to understand the causal and therapeutic potential of the ‘second genome’.
Click here to learn more.
Click here to view the agenda.
Click here to register.

World Vaccine Congress Europe: Changing the paradigm and finding a sustainable way to tackle AMR - The need for alternatives to antibiotics
2020-10-19 04:05 (America/New_York) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
CARB-X speakers include Ed Buurman, Alliance Director.
Topics covered include:

How big is the problem economically speaking?
Should we phase out broad-spectrum antibiotics?
Programmatic & technical challenges
What can vaccines bring?

Click here to view the agenda.
Click here to learn more.
Click here to register.

IDWeek 2020
2020-10-21 - 2020-10-25 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
To learn more, click here.
To view the program, click here.
To register, click here.

38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2020)
2020-10-26 - 2020-10-29 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
The 38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2020) will be held on 26-29 October 2020 as a fully virtual meeting.
The organization of the meeting is a joint effort of ESPID members from the Netherlands. The ESPID forms the basis for investigators interested in infectious diseases in children and infection prevention in childhood. The main intent of the meeting is to bring together the most prominent researchers in and relevant to the field of paediatric infectious diseases and immunology. The meeting will provide an opportunity to exchange knowledge and generate new ideas in a relaxed, smart albeit casual atmosphere.
To learn more, click here.
To view the program, click here.
To register, click here.

BARDA Industry Day
2020-10-27 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
BARDA Industry Day is the annual meeting held to increase potential partner’s awareness of U.S. Government medical countermeasure priorities, interact with BARDA and ASPR staff, and network with public and private sector colleagues working in the Health Security space. This year, BARDA Industry Day 2020 will be virtual and will feature one day of exciting speakers, breakout sessions, and valuable networking opportunities! The primary mission of BARDA’s industry day is to advance innovation and development of medical countermeasures, bring together potential collaborators from across organizations, share our accomplishments among our stakeholders, and provide BARDA’s vision for the upcoming year’s priorities.
BARDA, through the CARB-X and Drive programs, is supporting a networks of wrap-around-service-oriented accelerators that can be leveraged to prepare partners for donor funding. The hope is to fill and maintain a pipeline of partners ready and able to apply for advanced research support while bolstering the market of life-saving countermeasures. DRIVE and CARB-X will organize a panel of BARDA supported accelerators who will describe how “wrap-around services” have actually lead to better products (fitting the BID theme of ‘responding together’. At the end of the panel, we will moderate a Q&A with audience members. Promotional material from other accelerators will be made available digitally for audience members.
To learn more, click here.

Live Webinar: GARDP/REVIVE – Developing antibiotics for children – medical need and regulatory challenges
2020-10-28 04:00 - 05:30 (America/New_York)
Speakers:
Phoebe Williams, Sydney Children’s Hospital and University of Sydney (Australia), will discuss:

Status quo – what antibiotics do we have (left) for children and babies
Where is the biggest medical need?
Challenges of clinical trials in children – the clinicians perspective
What impact will new drugs have in day-to-day practice and how does this depend on the setting (e.g. LMICs vs. high-income; community vs. hospital)?

Irja Lutsar, University of Tartu (Estonia), will discuss:

Clinical development of antibiotics for children; incl. new formulations of existing antibiotics including general regulatory requirements
Brief overview of the type of data required for a new antibiotic for paediatric use; i.e. PK and other data
Challenges of clinical trials in children and babies – the drug developers/regulatory perspective

Moderator: Sally Ellis (GARDP)
The presentations will be followed by a Q&A session.
To learn more, click here.

Interdisciplinary Course on Antibiotics and Resistance (ICARe) Webinar:
2020-10-29 16:00 - 18:00 (Europe/Paris) | Webinar
Panelists include Erin Duffy, CARB-X Chief of R&D
Please join us for a special ICARe webinar in light of the course’s 5th anniversary. This two-hour event, hosted by ICARe director Patrice Courvalin (Institut Pasteur, France), will feature four 20-minute presentations from leading experts in antimicrobial resistance and antibiotic discovery research. Presentations will follow with a 30-minute panel discussion.
The webinar schedule is as follows:

4:00: Patrice Courvalin (Institut Pasteur, France) – Introduction
4:05: Helen Boucher (Tufts Medical Center, USA) – “Syndemics of AMR and COVID”
4:25: Gerry Wright (McMaster University, Canada) – “What’s new in antibiotic resistance?”
4:45: Erin Duffy (CARB-X, USA) – “Innovation in antibiotic discovery”
5:05: John Rex (F2G, UK)- “Prospects and remaining challenges in antibiotic development”
5:25: Panel Discussion
5:55: Patrice Courvalin (Institut Pasteur, France) – Closing Remarks

To learn more, click here.
To register, click here.
After registering, you will receive a confirmation email containing information about joining the webinar. Please note that the webinar start time is in Paris Time.​

Antimicrobial Resistance Fighter Coalition Webinar: Aiming in the dark: what happens when disease spreads without diagnosis
2020-11-05 09:00 - 10:00 (America/New_York) | Webinar
Panelists include Erin Duffy, CARB-X Chief of R&D
AMR in the Light of COVID-19 – A Webinar Series
Each of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world.
About this Webinar:
The pandemic has demonstrated the critical role of diagnostic testing to steer our public health response. It has been shown that diagnostic testing for bacterial and fungal infections results in improved use of antibiotics and antibiotic stewardship. But whereas testing for COVID-19 has benefited from innovation and rapid uptake, testing for drug resistant infections remains underutilized. How can we improve the effective use of diagnostics, globally, for the diagnosis of bacterial and viral infections?
To learn more about the Antimicrobial Resistance Fighter Coalition, click here.
To learn more about this webinar series, click here.
To register for this webinar, click here.

FDA Public Workshop: Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs
2020-11-16 | Webinar
The Food and Drug Administration (FDA, the Agency, or we) is hosting a virtual public meeting entitled “Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs.” The purpose of the meeting is to obtain early input from the public on a potential revised approach for considering the human medical importance of antimicrobial new animal drugs when assessing and managing the antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. The Agency is seeking public input on a potential revised process for ranking antimicrobials according to their relative importance in human medicine, on the potential criteria for their ranking, and on the resulting ranked list of antimicrobial drugs. A concept paper describing this potential revised process will be made available for discussion at the public meeting.
Click here to learn more.
Click here for the concept paper posted in advance of the meeting.

CARB-X WEBINAR: Tackling Drug-resistant Bacteria: Exciting Science in the CARB-X Portfolio - Vedanta, Eligo, Peptilogics
2020-11-17 10:00 - 11:00 (America/New_York) | Webinar
Join us Tuesday, November 17, at 10 AM – 11 AM ET for an update on CARB-X, and an insider’s look at 3 innovative programs supported by CARB-X
CARB-X is hosting this special webinar to showcase some of the exciting science in the CARB-X portfolio and the progress CARB-X is making supporting the development of innovative therapeutics, preventatives and rapid diagnostics to address antibiotic-resistant bacteria.
The webinar will be moderated by Kevin Outterson, Executive Director of CARB-X, and will feature

Erin Duffy, CARB-X R&D Chief, on portfolio priorities and progress
Xavier Duportet, Co-Founder and CEO of Eligo Bioscience, on Eligo’s innovative CRISPR-based therapeutics derived from bacteriophages to prevent and treat antibiotic-resistant infections in transplant patients
Jonathan Steckbeck, Founder and CEO of Peptilogics, on the development of their first-in-class antibiotic peptide for the treatment of prosthetic joint infections which recently was granted Orphan Drug Designation by the US Food and Drug Administration
Bernat Olle, Co-Founder and CEO of Vedanta Biosciences, on Vedanta’s microbiome program, including VE707, an oral therapeutic designed to restore a patient’s healthy microbiota to that it can fight multidrug-resistant bacteria, and VE303, which has recently become the first CARB-X-funded therapeutic to go on to secure BARDA support for late-stage development, and is also the first-ever BARDA award for research and development of a live bio-therapeutic product.

A virtual Q&A will also be held.
CLICK HERE TO REGISTER TODAY:
Once you register, you will receive a confirmation and will be able to download an invitation to your calendar.

Live Webinar: GARDP/REVIVE – Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)
2020-11-17 11:00 - 12:30 (America/New_York) | Webinar
Speakers:

James J. Collins, Termeer Professor of Medical Engineering & Science Professor, Broad Institute of MIT and Harvard (USA)
Cesar de la Fuente, Presidential Assistant Professor, University of Pennsylvania (USA)
Henriette Willems, Senior Research Associate, The ALBORADA Drug Discovery Institute, University of Cambridge, (UK)
Fredrik Svensson, Senior Research Associate, UCL Drug Discovery Institute, London, (UK)

Moderator:

Laura Piddock, Director of Scientific Affairs, GARDP

In this webinar, the speakers will give an overview of their work on the discovery of antibiotics through the use of artificial intelligence. The session will include the following presentations:

Deep learning approaches to antibiotic discovery – James J. Collins
Antibiotic discovery by means of computers – Cesar de la Fuente
Computational Chemistry on a Budget – Henriette Willems & Fredrik Svensson

To learn more, click here.

World Antimicrobial Awareness Week 2020
2020-11-18 - 2020-11-24 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
The theme for World Antimicrobial Awareness Week 2020 for the human health sector is “United to preserve antimicrobials.”
Every year, World Antimicrobial Awareness Week aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices among the general public, health workers and policy makers to stop the further emergence and spread of drug-resistant infections.
WAAW has expanded its scope to address not just antibiotics, but all antimicrobials, including antiviral, antifungal and antiparasitic medicines. This exciting decision came on the strong recommendation of the antimicrobial resistance (AMR) community. In the midst of a global pandemic, stakeholders came together virtually to discuss the challenges and opportunities for the WAAW campaign and awareness of Antimicrobial Resistance (AMR) more generally. The overarching message was that all sectors needed to unite to change behaviours and that the campaign needed to broaden its scope from antibiotics, to include all antimicrobials.
For the first time ever, we are also celebrating WAAW at a time when traditional methods of campaigning are not possible. We are challenged by new rules of social distancing, limitations on public gatherings, and physical isolation. As with the global virtual consultation in May 2020, however, the AMR community has shown its commitment, resilience and eagerness to celebrate, unite, and build awareness around an issue that is becoming one of the most significant challenges to our global health and development objectives. Over the 7 days of WAAW 2020, events will be held virtually in all regions of the world, by governments, academics, students, health care workers, NGOs and all those interested and passionate about combating AMR.
To learn more, click here.

Emerging Antimicrobials and Diagnostics in AMR 2020
2020-11-18 09:30 - 17:45 (Europe/Amsterdam) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
CARB-X participants include Nadia Cohen, Alliance Manager, who will present during the Accelerating AMR R&D section of the program at 10:40 EST, and Betsy Wonderly Trainor, Alliance Director, who will present at 10:20 EST.
Learn about the latest AMR technologies in a series of interactive key note lectures by international Captains of Industry and Leading Scientists.
Interactive, one day online event providing an international podium for emerging preventives, antimicrobial strategies, microbial diagnostics and related (platform) technologies: key note lectures, technology and product updates, frontline stories and concluding Q&A session.
The event is composed of 3 building sections:
I: Setting the scene of AMR R&D (09:30 – 12:30 AM)
II: Technology and Product Updates in AMR (01:00 – 03:50 PM)
III: Accelerating AMR R&D (04:00 – 05:45 PM).
Date: 18 November, 2020; 09:30 AM – 05:45 PM CET
The event is delivered digitally in collaboration with KIT Royal Tropical Institute in Amsterdam and marks the beginning of the World Antimicrobials Awareness Week.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Wellcome Trust Webinar: The Global Response to drug-resistant infections - momentum, success and critical gaps
2020-11-18 10:00 - 11:00 (America/New_York) | Webinar
Over the last year, Wellcome has mapped the global response to AMR to identify progress made since the UN High-Level Meeting on AMR held in 2016. The analysis captures the views of over 150 experts and reviewed more than 250 documents and aims to bring all this together in a critical path for what the global response to AMR could look like now, and beyond 2030.
Recognizing the impact of Covid-19, the work was expanded to understand if the pandemic has changed how we position efforts to address AMR. The work has been critical in informing Wellcome’s strategic approach toward ending drug-resistant infections and we hope it will benefit other stakeholders by helping to inform where urgent focus is needed.
Join us for the launch of this important piece of work, reflect on what it means to you and your work and hear the reactions of others.
You can download the full report here.
To learn more, click here.
To view the agenda, click here.
To register, click here.

The meeting will start at 3PM GMT / 10AM EST

Antimicrobial Resistance Fighter Coalition Webinar: Responding to difficult-to-treat infections: Role and responsibilities of governments, researchers, clinicians, industry and patients
2020-11-19 09:00 - 10:00 (America/New_York) | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States

Live Webinar: GARDP/REVIVE – Saving childrens’ lives – treating neonatal sepsis
2020-11-20 04:30 - 06:00 (America/New_York)
Speakers:

Prof Hanan Balkhy, Assistant Director-General for Antimicrobial resistance, WHO
Dr Manica Balasegaram, Executive Director, GARDP – Dr Dhanya Dharmapalan, paediatrician and member of the Pediatric Infectious Disease Society (PIDS), Mumbai
Dr Borna Nyaoke, Senior Clinical Project Manager, DNDi/GARDP Kenya

Moderator:

Dr Peter Beyer, Senior Advisor, AMR Division, WHO The presentations will be followed by a Q&A session.

The webinar, organized in collaboration with WHO, is being held on the occasion of Universal Children’s Day and during World Antimicrobial Awareness Week. It will focus on the challenges in treating newborns suffering from drug-resistant sepsis and finding new treatment options.
To learn more, click here.
